Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ticagrelor 90 mg Clear all
Withdrawn Phase 2 Interventional

Ticagrelor vs. Prasugrel Effects on Infarct Size

NCT02507323
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ticagrelor, prasugrel, Placebo
Drug
Lead sponsor
Yochai Birnbaum
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antithrombotic Effects of Ticagrelor Versus Clopidogrel

NCT01642238
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 5, 2026, 8:15 AM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Terminated Phase 4 Interventional Results available

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

NCT02291419
View directory record Official record
Conditions
Myocardial Injury
Interventions
ticagrelor, aspirin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • Little Rock, Arkansas • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

NCT03928353
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Tailored Antiplatelet Therapy Following PCI

NCT01742117
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

NCT02053909
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

NCT02016170
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 5, 2026, 8:15 AM EDT
Recruiting Phase 4 Interventional

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

NCT06691191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 90 mg, Prasugrel 10 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6140 Oral Contraceptive Interaction Study

NCT00685906
View directory record Official record
Conditions
Healthy
Interventions
AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT02081443
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Crossover Trial of Clopidogrel and Ticagrelor

NCT03161678
View directory record Official record
Conditions
Myocardial Infarction, Thrombosis, Platelet Dysfunction
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

NCT02091921
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ticagrelor
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

NCT04702113
View directory record Official record
Conditions
Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions
Cipherome Lighthouse Pilot
Diagnostic Test
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
13,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
290
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 5, 2026, 8:15 AM EDT